02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
03:26 , Jun 3, 2017 |  BioCentury  |  Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
07:00 , Oct 24, 2016 |  BioCentury  |  Emerging Company Profile

RORing against resistance

  Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. The Bruton’s tyrosine kinase...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

TK216: Phase I started

Oncternal dosed the first patient an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate IV TK216 in about 45 patients ages >=12. Oncternal gained the compound from its June merger with Tokalas Inc. (see...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

Oncternal, Tokalas deal

Cancer companies Oncternal and Tokalas merged and will retain the Oncternal name. Oncternal’s cirmtuzumab (UC-961), a humanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1), is in Phase I testing to treat relapsed...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Jul 24, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of Ewing's sarcoma with cell-specific expression of a transgenic Ewing sarcoma breakpoint region 1 (EWSR1; EWS)-Friend leukemia virus integration 1 (FLI1) fusion protein...
08:00 , Jan 27, 2014 |  BioCentury  |  Emerging Company Profile

Salarius: Kicking LSD

Salarius Pharmaceuticals LLC is using a fragment-based discovery approach to develop safer inhibitors of lysine-specific histone demethylase, an epigenetic target that is up-regulated in hormone-dependent cancers and essential in specific forms of acute myelogenous leukemia...
07:00 , Apr 26, 2012 |  BC Innovations  |  Cover Story

Cancer cell line encyclopedias

Two research teams have independently developed large-scale screening platforms to profile hundreds of human cancer cell lines and identify drug sensitivity biomarkers. 1,2 Novartis AG , a member of one of the groups, is now...